Gleanboots Life Science Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 7.50 M
- Company Age 25 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 93.24%
- Profit Growth 128.33%
- Ebitda 72.99%
- Net Worth 12.47%
- Total Assets 25.07%
About Gleanboots Life Science
Gleanboots Life Science Private Limited (GLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 October 1999 and has a history of 25 years and four months. Its registered office is in Delhi, India.
The Corporate was formerly known as Pol Pharma (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M, as per Ministry of Corporate Affairs (MCA) records.
Yogesh Kumar and Harsh Kansal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239DL1999PTC101791
- Company No.
101791
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Oct 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Gleanboots Life Science?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Kumar  | Director | 01-Dec-2014 | Current |
| Harsh Kansal | Director | 14-Mar-2017 | Current |
Financial Performance of Gleanboots Life Science.
Gleanboots Life Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 93.24% increase. The company also saw a substantial improvement in profitability, with a 128.33% increase in profit. The company's net worth Soared by an impressive increase of 12.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gleanboots Life Science?
In 2023, Gleanboots Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eureka Greenlands LimitedYogesh Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gleanboots Life Science?
Unlock and access historical data on people associated with Gleanboots Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gleanboots Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gleanboots Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
